South Korea · Delayed Price · Currency is KRW Keeps Biopharma Statistics
Total Valuation
Keeps Biopharma has a market cap or net worth of KRW 129.30 billion. The enterprise value is 211.61 billion.
| Market Cap | 129.30B |
| Enterprise Value | 211.61B |
Important Dates
The last earnings date was Thursday, May 28, 2026.
| Earnings Date | May 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Keeps Biopharma has 20.08 million shares outstanding. The number of shares has increased by 5.60% in one year.
| Current Share Class | 20.08M |
| Shares Outstanding | 20.08M |
| Shares Change (YoY) | +5.60% |
| Shares Change (QoQ) | +0.78% |
| Owned by Insiders (%) | 4.13% |
| Owned by Institutions (%) | 4.24% |
| Float | 14.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.68 |
| PB Ratio | 1.52 |
| P/TBV Ratio | 9.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 56.23, with an EV/FCF ratio of -4.96.
| EV / Earnings | -88.84 |
| EV / Sales | 1.12 |
| EV / EBITDA | 56.23 |
| EV / EBIT | n/a |
| EV / FCF | -4.96 |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 1.11.
| Current Ratio | 1.26 |
| Quick Ratio | 0.67 |
| Debt / Equity | 1.11 |
| Debt / EBITDA | 17.13 |
| Debt / FCF | -2.22 |
| Interest Coverage | 0.11 |
Financial Efficiency
Return on equity (ROE) is -4.19% and return on invested capital (ROIC) is 0.55%.
| Return on Equity (ROE) | -4.19% |
| Return on Assets (ROA) | 0.24% |
| Return on Invested Capital (ROIC) | 0.55% |
| Return on Capital Employed (ROCE) | 0.54% |
| Weighted Average Cost of Capital (WACC) | 8.77% |
| Revenue Per Employee | 1.73B |
| Profits Per Employee | -21.85M |
| Employee Count | 109 |
| Asset Turnover | 0.89 |
| Inventory Turnover | 5.74 |
Taxes
| Income Tax | -1.33B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.95% in the last 52 weeks. The beta is 1.19, so Keeps Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -60.95% |
| 50-Day Moving Average | 7,676.60 |
| 200-Day Moving Average | 9,616.80 |
| Relative Strength Index (RSI) | 38.71 |
| Average Volume (20 Days) | 114,128 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Keeps Biopharma had revenue of KRW 188.94 billion and -2.38 billion in losses. Loss per share was -119.33.
| Revenue | 188.94B |
| Gross Profit | 38.61B |
| Operating Income | 821.73M |
| Pretax Income | -4.58B |
| Net Income | -2.38B |
| EBITDA | 5.53B |
| EBIT | 821.73M |
| Loss Per Share | -119.33 |
Balance Sheet
The company has 31.06 billion in cash and 94.78 billion in debt, with a net cash position of -63.72 billion or -3,173.58 per share.
| Cash & Cash Equivalents | 31.06B |
| Total Debt | 94.78B |
| Net Cash | -63.72B |
| Net Cash Per Share | -3,173.58 |
| Equity (Book Value) | 85.23B |
| Book Value Per Share | 3,292.39 |
| Working Capital | 24.18B |
Cash Flow
In the last 12 months, operating cash flow was -10.03 billion and capital expenditures -32.66 billion, giving a free cash flow of -42.69 billion.
| Operating Cash Flow | -10.03B |
| Capital Expenditures | -32.66B |
| Depreciation & Amortization | 4.71B |
| Net Borrowing | 44.96B |
| Free Cash Flow | -42.69B |
| FCF Per Share | -2,126.10 |
Margins
Gross margin is 20.44%, with operating and profit margins of 0.43% and -1.26%.
| Gross Margin | 20.44% |
| Operating Margin | 0.43% |
| Pretax Margin | -2.42% |
| Profit Margin | -1.26% |
| EBITDA Margin | 2.93% |
| EBIT Margin | 0.43% |
| FCF Margin | n/a |
Dividends & Yields
Keeps Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.60% |
| Shareholder Yield | -5.60% |
| Earnings Yield | -1.84% |
| FCF Yield | -33.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 20, 2020. It was a forward split with a ratio of 3.
| Last Split Date | May 20, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Keeps Biopharma has an Altman Z-Score of 1.79 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.79 |
| Piotroski F-Score | 4 |